Clinical Trial Search

Primary: Positive Predictive Value (PPV) of EC/EG in a Non-GERD Population That Has Three or More Non-GERD Risk Factors for BE. — 33 Percentage of screened participants

Primary: Cytosponge Acceptability by Number of Participants — 46; 81; 2; 6 Participants

Primary: Comparative Histopathology-confirmed Measures of Per Lesion Sensitivity and Per Lesion Specificity, by Using pCLE Associated With WLE, or WLE Alone, for the Detection of…

Primary: Number of Participants Reporting Each Category of Tolerance Assessed by the Tolerance Survey — 96; 31; 1; 121 number of participants

Primary: Reversal of Oxidative DNA Damage as Assessed by Changes in 8-hydroxy-2' -Deoxyguanosine (8OHdG) Immunostaining — 1.62 % of strongly/moderately stained nuclei — p=0.54

Primary: Number of Subjects That Would Have This Procedure Again — 19; 16 Participants

Primary: Diagnostic Yield for Neoplasia in High Risk Patients(Suspected Neoplasia) — 34; 17 percent yield for neoplasia — p=0.01

Primary: Level of Dysplasia on Histology at 12 Months — 10; 11; 15; 2 paricipants — p=0.0098

Primary: 7 Days Post-EGD Impact of Events Score (IES) — 1.42; 1.21; 0 units on a scale

Primary: First Event of Death, Oesophageal Adenocarcinoma, High Grade Dysplasia — 127; 154; 174; 139 Participants — p=0.068

Primary: Change in Ki67 Biomarker Expression — 1539; 1556; 1575; 1864 cells/mm^2

Primary: Percentage of Subjects Who Agreed to Participated in the Esophageal Assessment — 40.7; 45.7; 47.5 percentage of participants — p=0.25

Primary: Protection Against DNA Damage by UDCA — 1.068; .82 Relative Densitometry Units

Primary: Mean Ki67 Expression — 35.6; 307.8 cells/mm2

Primary: Procedure Preference and Acceptability Questionnaire and Visual Analog Scale — 7.2; 8.5; -1.3; 16.2 Units on a scale

Primary: Change in Mean Tissue Prostaglandin E2 (PGE2) Concentration as Determined From Barrett's Research Mucosal Biopsy Samples — -67.6; -123.9; -174.9 pg/mL — p=0.0955

Primary: Eradication of Barrett's Esophagus — 2 Participants

Primary: Median Tolerability Score on 10-point Visual Analog Scale (VAS) — 7; 8; 8; 8 units on a scale

Primary: Number of Participants With Complete Eradication of Esophageal Dysplasia — 51 Participants

Primary: Percentage of Participants With Histological Clearance of Barrett's Metaplasia — 100; 20; 78; 82 Percent of Participants

Primary: The % of Patients With Complete Eradication of Intestinal Metaplasia (IM) at 12 Month — 85; 81.5 percentage of participants

Primary: The Impact of EsoCheck/EsoGuard on Provider's Decision for Upper Endoscopy Referral — 382; 211 Cases

Primary: Number of Participants With Tolerability of the Procedure — 6 Participants

Primary: Percentage of Correctly Identified Positive (Dysplastic) Biopsies — 100.0 percentage of correct identifications

Primary: Change in Serum PGE2 Levels — 4.44; -21.65 Percentage of change in serum PGE2 level

Primary: Percent Change in Median pS6K1 Immunostaining Among Participants With Barrett Esophagus — 1.4; -14.7 percentage of change — p=0.7981

Primary: Percentage of Patients With Successful Eradication — 45.5; 38.1; 36.4; 19.04 percentage of participants

Primary: Feasibility for Imaging of Esophagus Using an SECM Tethered Endoscopic Capsule. — 3 Participants

Primary: Change in Inflammation Biomarker Tissue PGE2 Level — 1.35; -0.02; 1.19; -0.06 nanograms/gram of tissue — p=0.30

Primary: Complete Response — 81 Participants